Table 1.
Patient characteristics at treatment initiation. Results are Mean ± SD. Control groups are patients that were not treated during the study duration.
Control | RAL | EFV | |
---|---|---|---|
Age at treatment initiation (y) | 42.4 (14) | 42.5 (10) | 40.7 (8) |
Ethnicity % (n) | |||
Israeli Jew | 33.3 (5) | 26.6 (4) | 26.6 (4) |
Israeli Arab | 0 (0) | 13.3 (2) | 40 (6) |
Ethiopian Jew | 46.6 (7) | 26.6 (4) | 6.6 (1) |
Former USSR | 13.3 (2) | 13.3 (2) | 6.6 (1) |
Other | 6.6 (1) | 20 (3) | 20 (3) |
Smoking (Y/N) | 4/8 | 5/9 | 5/8 |
Alcohol (Y/N) | 1/10 | 3/11 | 3/10 |
Time from diagnosis to treatment initiation (days) | 428 (937) | 858 (1331) | 1301 (1269) |
CD4-treatment initiation (cells/μl) | 516 (192) | 195 (178) | 220 (173) |
VL at treatment imitation (copies/ml) | 28,000 (32000) | 204,000 (333,000) | 77,000 (111,000) |
BMI at treatment initiation kg/M2 | 25.3 (4.2) | 26 (3.6) | 23 (3.2) |
Nadir CD4 (cells/μl) | 317.3 (156) | 194.8 (157) | 210.6 (142) |
OH-25 vitamin D (ng/dl) | 27 (18) | 23.2 (14) | 22.7 (13) |
Albumin-corrected calcium (mmol/L) | 2.0 (0.3) | 2.2 (0.2) | 2.1 (0.3) |
Phosphorus (mmol/L) | 1 (0.2) | 1 (0.3) | 1 (0.2) |
P1NP (ng/ml) | 47 (20) | 46 (17) | 55 (32) |
CTX (pg/ml) | 288 (264) | 341 (296) | 243 (161) |